<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000020.pub3" GROUP_ID="PREG" ID="502399072109450424" MERGED_FROM="" MODIFIED="2015-09-02 14:14:34 +0100" MODIFIED_BY="Leanne Jones" REVIEW_NO="0097" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2015-09-02 14:14:34 +0100" MODIFIED_BY="Leanne Jones">
<TITLE>Anti-D administration in pregnancy for preventing Rhesus alloimmunisation</TITLE>
<CONTACT MODIFIED="2015-09-02 14:14:34 +0100" MODIFIED_BY="Leanne Jones"><PERSON ID="60356844606532010941120319100008" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rosemary</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>McBain</LAST_NAME><EMAIL_1>rosie.mcbain@gmail.com</EMAIL_1><EMAIL_2>rosemary.mcbain@health.sa.edu.au</EMAIL_2><ADDRESS><DEPARTMENT>ARCH: Australian Research Centre for Health of Women and Babies, Robinson Research Institute, Discipline of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>The University of Adelaide</ORGANISATION><ADDRESS_1>Women's and Children's Hospital</ADDRESS_1><ADDRESS_2>72 King William Road</ADDRESS_2><CITY>Adelaide</CITY><ZIP>5000</ZIP><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-09-02 14:14:34 +0100" MODIFIED_BY="Leanne Jones"><PERSON ID="60356844606532010941120319100008" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rosemary</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>McBain</LAST_NAME><EMAIL_1>rosie.mcbain@gmail.com</EMAIL_1><EMAIL_2>rosemary.mcbain@health.sa.edu.au</EMAIL_2><ADDRESS><DEPARTMENT>ARCH: Australian Research Centre for Health of Women and Babies, Robinson Research Institute, Discipline of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>The University of Adelaide</ORGANISATION><ADDRESS_1>Women's and Children's Hospital</ADDRESS_1><ADDRESS_2>72 King William Road</ADDRESS_2><CITY>Adelaide</CITY><ZIP>5000</ZIP><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="15869" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Caroline</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Crowther</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>c.crowther@auckland.ac.nz</EMAIL_1><EMAIL_2>caroline.crowther@adelaide.edu.au</EMAIL_2><ADDRESS><DEPARTMENT>Liggins Institute</DEPARTMENT><ORGANISATION>The University of Auckland</ORGANISATION><ADDRESS_1>Private Bag 92019</ADDRESS_1><ADDRESS_2>85 Park Road</ADDRESS_2><CITY>Auckland</CITY><COUNTRY CODE="NZ">New Zealand</COUNTRY></ADDRESS></PERSON><PERSON ID="4841" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Philippa</FIRST_NAME><LAST_NAME>Middleton</LAST_NAME><POSITION>Senior Research Fellow</POSITION><EMAIL_1>philippa.middleton@adelaide.edu.au</EMAIL_1><EMAIL_2>mpm@ozemail.com.au</EMAIL_2><ADDRESS><DEPARTMENT>Women's and Children's Research Institute</DEPARTMENT><ORGANISATION>The University of Adelaide</ORGANISATION><ADDRESS_1>Women's and Children's Hospital</ADDRESS_1><ADDRESS_2>72 King William Road</ADDRESS_2><CITY>Adelaide</CITY><ZIP>5006</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-06-15 22:18:59 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="31" MONTH="5" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="5" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="5" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1996"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1996"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-08-12 11:24:08 +0100" MODIFIED_BY="Sonja L Henderson">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-08-12 11:24:08 +0100" MODIFIED_BY="Sonja L Henderson">
<DATE DAY="31" MONTH="5" YEAR="2015"/>
<DESCRIPTION>
<P>Search updated and one study added to 'Ongoing studies'. Addition of GRADE table.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-08-12 11:23:57 +0100" MODIFIED_BY="Sonja L Henderson">
<DATE DAY="31" MONTH="5" YEAR="2015"/>
<DESCRIPTION>
<P>New search for studies and content updated (no change to conclusions).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-05-06 03:50:57 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-05-06 03:50:57 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>One trial added to ongoing studies (<LINK REF="STD-CTRI_x002f_2008_x002f_091_x002f_000157" TYPE="STUDY">CTRI/2008/091/000157</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-11-17 11:13:14 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="9" YEAR="2012"/>
<DESCRIPTION>
<P>Format of review updated, including background format, methods, and results and discussion format. Characteristics of studies and 'Risk of bias' tables updated. Search updated and one report identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-12-20 15:28:41 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-12-20 15:28:46 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="3" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-29 10:53:55 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="6" YEAR="2007"/>
<DESCRIPTION>
<P>Search updated. No new trials identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-29 10:53:33 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="4" YEAR="2004"/>
<DESCRIPTION>
<P>No new studies found in current update. One paper placed in 'excluded studies' (plan for a trial unlikely to proceed). Odds ratio changed to relative risk. Text expanded (e.g. 'Background').</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-29 10:53:36 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="8" YEAR="2000"/>
<DESCRIPTION>
<P>New search for trials conducted but none found. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-29 10:51:13 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="1" YEAR="1999"/>
<DESCRIPTION>
<P>Search updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-06-07 06:00:03 +0100" MODIFIED_BY="Rosemary D McBain">
<INTERNAL_SOURCES MODIFIED="2012-09-12 13:39:15 +0100" MODIFIED_BY="Rosemary D McBain">
<SOURCE MODIFIED="2012-09-12 13:39:15 +0100" MODIFIED_BY="Rosemary D McBain">
<NAME>ARCH: Australian Research Centre for Health of Women and Babies, Robinson Institute, Discipline of Obstetrics and Gynaecology, The University of Adelaide</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2015-06-07 06:00:03 +0100" MODIFIED_BY="Rosemary D McBain">
<SOURCE>
<NAME>Australian Department of Health and Ageing</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2015-06-07 06:00:03 +0100" MODIFIED_BY="Rosemary D McBain">
<NAME>National Health and Medical Research Council to the Australian and New Zealand Satellite of the Pregnancy and Childbirth Cochrane Review Group</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-09-02 14:12:40 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-05-09 04:25:52 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-29 10:54:31 +0000" MODIFIED_BY="[Empty name]">Anti-D administration in pregnancy for preventing Rhesus alloimmunisation</TITLE>
<SUMMARY_BODY MODIFIED="2015-05-09 04:25:52 +0100" MODIFIED_BY="[Empty name]">
<P>Women whose blood group is Rh-negative sometimes form Rh-antibodies when carrying a Rh-positive baby, in response to the baby's different red blood cell make-up. This sensitisation is more likely to happen during birth, but occasionally occurs in late pregnancy. These antibodies can cause anaemia, and sometimes death, for a Rh-positive baby in a subsequent pregnancy. Giving the mother anti-D after the first birth is known to reduce this problem. This review assessed two trials with moderate to high risk of bias and found that giving anti-D during pregnancy may help as well, although more research is required to confirm these possible benefits and identify any possible harms.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-09-02 14:12:40 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-11-13 22:16:16 +0000" MODIFIED_BY="[Empty name]">
<P>During pregnancy, a Rhesus negative (Rh-negative) woman may develop antibodies when her fetus is Rhesus positive (Rh-positive). These antibodies may harm Rh-positive babies.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-08-14 07:36:03 +0100" MODIFIED_BY="Rosemary D McBain">
<P>To assess the effects of antenatal anti-D immunoglobulin on the incidence of Rhesus D alloimmunisation when given to Rh-negative women without anti-D antibodies.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-06-15 22:19:32 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 May 2015) and reference lists of retrieved studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-11-14 04:56:15 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trials in Rh-negative women without anti-D antibodies given anti-D after 28 weeks of pregnancy, compared with no treatment, placebo or a different regimen of anti-D.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-05-06 03:34:31 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-09-02 14:12:40 +0100" MODIFIED_BY="[Empty name]">
<P>We included two trials involving over 4500 women, comparing anti-D prophylaxis with no anti-D during pregnancy in this review. Overall, the trials were judged to be at moderate to high risk of bias. The quality of the evidence for pre-specified outcomes was also assessed using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach.</P>
<P>In regards to primary review outcomes, there did not appear to be a clear difference in the risks of immunisation when women who received anti-D at 28 and 34 weeks' gestation were compared with women who were not given antenatal anti-D: risk ratio (RR) for incidence of Rhesus D alloimmunisation during pregnancy was 0.42 (95% confidence interval (CI) 0.15 to 1.17, two trials, 3902 women; GRADE: <I>low quality evidence</I>); at birth of a Rh-positive infant the RR was 0.42 (95% CI 0.15 to 1.17, two trials, 2297 women); and within 12 months after birth of a Rh-positive infant the average RR was 0.39 (95% CI 0.10 to 1.62, two trials, 2048 women; Tau²: 0.47; I²: 39%; GRADE: <I>low quality evidence</I>). Neither of the trials reported on incidence of Rhesus D alloimmunisation in subsequent pregnancies.</P>
<P>Considering secondary outcomes, in one trial, women receiving anti-D during pregnancy were shown to be less likely to register a positive Kleihauer test (which detects fetal cells in maternal blood) in pregnancy (at 32 to 25 weeks) (RR 0.60, 95% CI 0.41 to 0.88; 1884 women; GRADE: <I>low quality evidence</I>) and at the birth of a Rh-positive infant (RR 0.60, 95% CI 0.46 to 0.79; 1189 women; GRADE: <I>low quality evidence</I>). No clear differences were seen for neonatal jaundice (RR 0.26, 95% CI 0.03 to 2.30; 1882 infants; GRADE: <I>very low quality evidence</I>). Neither of the trials reported on adverse effects associated with anti-D treatment.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-08-11 09:58:34 +0100" MODIFIED_BY="Heather Maxwell">
<P>Existing studies do not provide conclusive evidence that the use of anti-D during pregnancy benefits either mother or baby in terms of incidence of Rhesus D alloimmunisation during the pregnancy or postpartum, or the incidence of neonatal morbidity (jaundice) (<I>low to very low quality evidence</I>). However women receiving anti-D may be less likely to register a positive Kleihauer test in pregnancy and at the birth of a Rh-positive infant (<I>low quality evidence</I>). Fewer women who receive anti-D during pregnancy may have Rhesus D antibodies in a subsequent pregnancy, with benefits for the baby, however this needs to be tested in studies of robust design.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-09-02 14:03:55 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-08-11 10:00:35 +0100" MODIFIED_BY="Heather Maxwell">
<CONDITION MODIFIED="2015-06-16 12:10:08 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Rhesus incompatibility and haemolytic disease of the fetus/newborn</HEADING>
<P>Haemolytic disease of the fetus and newborn can occur when the baby's red blood cells are destroyed. The most common cause is rhesus incompatibility, when antibodies from a Rh-negative mother target and destroy 'foreign' red blood cells from a Rh-positive fetus (<LINK REF="REF-Chilcott-2002" TYPE="REFERENCE">Chilcott 2002</LINK>). Haemolytic disease was a major cause of perinatal mortality, morbidity and long-term disability until the 1970s.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pathogenesis</HEADING>
<P>Rh-negative mothers carrying a Rh-positive fetus may produce anti-D antibodies (anti-D) following small feto-maternal haemorrhages at birth (<LINK REF="REF-Chown-1954" TYPE="REFERENCE">Chown 1954</LINK>; <LINK REF="REF-Chilcott-2002" TYPE="REFERENCE">Chilcott 2002</LINK>). The production of anti-D antibodies occurs in response to the presence of fetal red blood cells in the maternal circulation; this maternal immune response towards the fetal Rhesus antigen is known as &#8216;sensitisation&#8217; or immunisation. It is believed to take between five and 15 weeks for such antibodies to appear in the maternal circulation following a sensitising event such as birth (<LINK REF="REF-Gunson-1976" TYPE="REFERENCE">Gunson 1976</LINK>). Sensitisation is believed to have no adverse health effects for the mother, and the first baby is usually not harmed, as the pregnancy is generally complete by the time that sensitisation has occurred. These maternal antibodies (directed against antigens inherited from the father) may, however cause haemolytic disease in subsequent pregnancies with Rh-positive fetuses.</P>
<P>In addition to feto-maternal haemorrhage at birth, events during pregnancy may lead to the production of maternal anti-D antibodies, and thus sensitisation may also occur during the antenatal period. As there is a direct, proportional relationship between the volume of fetal Rh-positive red blood cells to which a Rh-negative mother is exposed and the incidence of immunisation (<LINK REF="REF-Zipursky-1967" TYPE="REFERENCE">Zipursky 1967</LINK>; <LINK REF="REF-Jones-2004" TYPE="REFERENCE">Jones 2004</LINK>), sensitising events (in addition to birth) may include termination of pregnancy, miscarriage, and some invasive investigative procedures (<LINK REF="REF-Bowman-1996" TYPE="REFERENCE">Bowman 1996</LINK>). The majority of sensitisations are however, thought to be caused by occult or 'silent' transplacental haemorrhages (<LINK REF="REF-Chilcott-2002" TYPE="REFERENCE">Chilcott 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Health consequences for the fetus or newborn</HEADING>
<P>In a Rh-negative mother, maternal anti-D antibodies may cross the placenta and lead to the immune-mediated destruction of fetal red blood cells. This more rapid destruction of the fetal red blood cells than normal, known as haemolytic disease of the fetus or newborn, can lead to anaemia and jaundice and in very severe cases, kernicterus (a form of brain damage caused by very high levels of bilirubin), or even death. A survey of 124 sensitised women showed that about 70% of their pregnancies were affected by some degree of haemolytic disease (<LINK REF="REF-Craig-1998" TYPE="REFERENCE">Craig 1998</LINK>). It has been estimated that approximately half of newborn infants with haemolytic disease are mildly affected, requiring no treatment. Of the remainder, half will become hydropic in utero, and half will be born apparently healthy but without treatment may die of kernicterus or be left severely disabled (<LINK REF="REF-Bowman-1965" TYPE="REFERENCE">Bowman 1965</LINK>).</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2015-08-11 10:00:20 +0100" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="3">Anti-D administration for preventing Rhesus alloimmunisation</HEADING>
<P>In the 1960s, Stern found that sensitisation to Rh-positive blood could be prevented by administering anti-D (<LINK REF="REF-Stern-1961" TYPE="REFERENCE">Stern 1961</LINK>). Anti-D gammaglobulin is a sterile solution containing anti-D immunoglobulin G (IgG) antibodies manufactured from a pooled source of plasma of males and post-menopausal women. The donors must be Rh-negative and can be immunised to stimulate their immune system to produce anti-D or to increase their anti-D titre.</P>
<P>When anti-D gammaglobulin became available in the early 1970s, deaths from haemolytic disease dramatically reduced, with postpartum administration effectively protecting against Rhesus alloimmunisation when properly used (<LINK REF="REF-Gravenhorst-1989" TYPE="REFERENCE">Gravenhorst 1989</LINK>; <LINK REF="REF-Crowther-1997" TYPE="REFERENCE">Crowther 1997</LINK>). Postpartum prophylaxis has been shown to be effective in reducing the incidence of alloimmunisation six months after administration and in a subsequent pregnancy in a Cochrane review of six randomised controlled trials (<LINK REF="REF-Crowther-1997" TYPE="REFERENCE">Crowther 1997</LINK>). The benefits were seen when anti-D was given within 72 hours of birth, regardless of the ABO blood group status of the mother and baby. Higher doses were more effective than lower doses (<LINK REF="REF-Crowther-1997" TYPE="REFERENCE">Crowther 1997</LINK>).</P>
<P>However, as sensitising events may also occur during pregnancy, postpartum anti-D will not prevent Rhesus alloimmunisation which occurs in the antenatal period. Although Zipursky and Israels (<LINK REF="REF-Zipursky-1967" TYPE="REFERENCE">Zipursky 1967</LINK>) proposed that anti-D could reduce the incidence of Rhesus alloimmunisation during pregnancy in Rh-negative mothers nearly forty years ago, it may still occur, either because insufficient anti-D is given after known sensitising events during pregnancy (or after birth), it is not given soon enough (within 72 hours), or due to silent feto-maternal haemorrhage.</P>
<P>A transplacental haemorrhage from fetus to mother can be detected by the Kleihauer test (which detects the presence and estimates the amount of fetal cells in maternal blood). Injection of anti-D will destroy these fetal cells and thus prevent sensitisation of the mother. The Kleihauer test will indicate how much anti-D is likely to be required.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antenatal prophylaxis - routine or universal anti-D administration in pregnancy</HEADING>
<P>As occult or &#8216;silent&#8217; sensitising events are thought to constitute the majority of sensitisations (<LINK REF="REF-Chilcott-2002" TYPE="REFERENCE">Chilcott 2002</LINK>), routine anti-D prophylaxis during pregnancy for Rh-negative mothers has been proposed and implemented in many countries (<LINK REF="REF-Engelfriet-2003" TYPE="REFERENCE">Engelfriet 2003</LINK>). This is intended to supplement the practices of postpartum administration of anti-D, and of offering anti-D prophylaxis to Rh-negative women who experience a known potentially sensitising event (such as miscarriage or threatened miscarriage) during their pregnancy. A recent meta-analysis, including studies with historical controls in addition to those with concurrent controls suggested that there is strong evidence for the effectiveness of routine antenatal anti-D prophylaxis for preventing sensitisation, in support of offering routine prophylaxis to all non-sensitised pregnant Rh-negative women (<LINK REF="REF-Turner-2012" TYPE="REFERENCE">Turner 2012</LINK>).</P>
<P>About 10% of all pregnancies involve a Rh-negative mother with a Rh-positive fetus; and in a first pregnancy, about 60% of Rh-negative women will have a Rh-positive baby (<LINK REF="REF-Chilcott-2002" TYPE="REFERENCE">Chilcott 2002</LINK>). Clearly if the father is known to be Rh-negative, the baby will also be Rh-negative and therefore anti-D would not be needed. However, for antenatal prophylaxis, the Rhesus status of the fetus is usually not yet known, and so all non-sensitised Rh-negative mothers would generally need to be offered routine anti-D. This means that approximately 40% of women carrying Rh-negative babies would have anti-D unnecessarily.</P>
<P>Routine antenatal anti-D prophylaxis is usually not administered until 28 weeks&#8217; gestation, since transplacental haemorrhages large enough to cause sensitisation do not usually occur until the third trimester (<LINK REF="REF-Contreras-1998" TYPE="REFERENCE">Contreras 1998</LINK>) and thus Rhesus antibodies usually develop after the 28th week of gestation (<LINK REF="REF-Davey-1979" TYPE="REFERENCE">Davey 1979</LINK>). The half-life of anti-D antibodies is estimated to be, on average, 17 to 22 days (<LINK REF="REF-Bishler-2003" TYPE="REFERENCE">Bishler 2003</LINK>). The two main approaches, a single 1500 international units (IU) dose at 28 weeks and 500 to 625 IU doses at 28 and 32 weeks, each theoretically ensure that 12 weeks after administration there is enough anti-D to protect against 1 mL of red blood cells or 2 mL of whole blood (<LINK REF="REF-Mackenzie-2006" TYPE="REFERENCE">Mackenzie 2006</LINK>). It is considered extremely unlikely that the volume of an antenatal transplacental haemorrhage would exceed 1 mL of fetal red blood (<LINK REF="REF-Mackenzie-2006" TYPE="REFERENCE">Mackenzie 2006</LINK>).</P>
<P>Anti-D administration has been widely regarded as a safe prophylactic intervention. Numerous studies have suggested that while small amounts of passive anti-D may cross the placenta, the antenatal administration of anti-D IgG does not have adverse consequences for the fetus (<LINK REF="REF-Liumbruno-2010" TYPE="REFERENCE">Liumbruno 2010</LINK>). However, since anti-D is derived from pooled donor plasma, there is a potential, or at least theoretical, risk of transmission of blood-borne diseases (<LINK REF="REF-National-Blood-2003" TYPE="REFERENCE">National Blood 2003</LINK>).</P>
<P>Some countries experience problems in obtaining sufficient supplies of anti-D, and so antenatal prophylaxis may be restricted to Rh-negative women expecting their first baby (partial rather than universal prophylaxis).</P>
<P>The effects of offering routine or universal antenatal anti-D prophylaxis to non-sensitised Rh-negative women is the focus of this systematic review.</P>
</SUBSECTION>
</INTERVENTION>
<THEORY MODIFIED="2015-08-11 10:00:35 +0100" MODIFIED_BY="Heather Maxwell">
<P>The precise mechanism whereby administration of anti-D immunoglobulin prevents alloimmunisation remains unclear (<LINK REF="REF-Kumpel-2001" TYPE="REFERENCE">Kumpel 2001</LINK>). Passive anti-D causes rapid and non-inflammatory clearance of passive anti-D coated red blood cells, which stops the inflammatory destruction of fetal red blood cells, evoking a natural immune response (<LINK REF="REF-Coopamah-2003" TYPE="REFERENCE">Coopamah 2003</LINK>). In addition, antibody-mediated immune suppression is believed to lead to the down-regulation of maternal immature dendritic cells or anti-D-specific B cells before the anti-D response develops (<LINK REF="REF-Kumpel-2002" TYPE="REFERENCE">Kumpel 2002</LINK>; <LINK REF="REF-Boruchov-2005" TYPE="REFERENCE">Boruchov 2005</LINK>).</P>
<P>It is considered unlikely that epitope masking (coating the fetal red blood cells with passive anti-D to allow them to evade detection by the maternal immune system), plays a significant role in the prevention of an anti-D response, as a large number of Rhesus D antigen sites on fetal red blood cells in the maternal circulation are not bound by passive anti-D (<LINK REF="REF-Kumpel-2002" TYPE="REFERENCE">Kumpel 2002</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2012-08-03 00:22:49 +0100" MODIFIED_BY="[Empty name]">
<P>The benefit of postpartum anti-D prophylaxis in reducing the incidence of alloimmunisation after administration and in a subsequent pregnancy has been established (<LINK REF="REF-Crowther-1997" TYPE="REFERENCE">Crowther 1997</LINK>). As occult or 'silent' sensitising events are thought to constitute the majority of sensitisations, it is important to assess whether routine or universal antenatal anti-D prophylaxis (to non-sensitised Rh-negative women) is effective in preventing Rhesus alloimmunisation and the potential adverse health consequences for the fetus and infant in the current pregnancy and/or in subsequent pregnancies.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-05-09 04:26:03 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of administering anti-D immunoglobulin at 28 weeks or more of pregnancy on the incidence of Rhesus D alloimmunisation during pregnancy (and/or in subsequent pregnancies) when given to Rh-negative women without anti-D antibodies.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-09-02 14:03:55 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-08-10 18:29:23 +0100" MODIFIED_BY="Heather Maxwell">
<CRIT_STUDIES MODIFIED="2015-05-02 07:00:14 +0100" MODIFIED_BY="[Empty name]">
<P>All published, unpublished and ongoing randomised, quasi-randomised and cluster-randomised trials. We will include studies published as abstracts only. We will exclude cross-over trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-05-09 04:26:03 +0100" MODIFIED_BY="[Empty name]">
<P>Rh-negative women without anti-D antibodies at 28 weeks' gestation.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-05-02 07:00:10 +0100" MODIFIED_BY="[Empty name]">
<P>Anti-D immunoglobulin at 28 weeks or more of gestation (regardless of timing, dose and route of administration), compared with no treatment or a placebo; or comparisons of different anti-D regimens.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-08-10 18:29:23 +0100" MODIFIED_BY="Heather Maxwell">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-08-10 18:29:23 +0100" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Incidence of Rhesus D alloimmunisation (during pregnancy, postpartum, and in subsequent pregnancies)</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-08-10 18:29:15 +0100" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Incidence of positive Kleihauer test (a test that detects fetal cells in the maternal blood)</LI>
<LI>Neonatal morbidity (e.g. neonatal jaundice, anaemia and kernicterus) in current or subsequent pregnancies</LI>
<LI>Adverse events attributed to anti-D treatment</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-09-02 14:03:17 +0100" MODIFIED_BY="[Empty name]">
<P>The following methods section of this review is based on a standard template used by the Cochrane Pregnancy and Childbirth Group.</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-06-15 22:22:03 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register by contacting the Trials Search Co-ordinator (31 May 2015).</P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from:</P>
<OL>
<LI>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE (Ovid);</LI>
<LI>weekly searches of Embase (Ovid);</LI>
<LI>monthly searches of CINAHL (EBSCO);</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts</LI>
</OL>
<P>Details of the search strategies for CENTRAL, MEDLINE, Embase and CINAHL, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>.</P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords.<BR/>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-06-15 22:22:40 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the reference lists of retrieved studies</P>
<P>We did not apply any language or date restrictions.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-09-02 14:03:55 +0100" MODIFIED_BY="[Empty name]">
<P>For methods used in the previous version of this review, <I>see </I>
<LINK REF="REF-Crowther-2013" TYPE="REFERENCE">Crowther 2013</LINK>.</P>
<P>For this update, the following methods were used, including to assess the one report that was identified as a result of the updated search. These methods are based on a standard template used by the Cochrane Pregnancy and Childbirth Group.</P>
<STUDY_SELECTION MODIFIED="2014-11-17 11:18:53 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed for inclusion all the potential studies identified as a result of the search strategy. We resolved any disagreement through discussion or, if required, we consulted the third review author.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-11-17 11:21:23 +0000" MODIFIED_BY="[Empty name]">
<P>We designed a form to extract data. For eligible studies, two review authors extracted the data using the agreed form. We resolved discrepancies through discussion or, if required, we consulted the third review author. Data were entered into Review Manager software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>) and checked for accuracy.</P>
<P>When information regarding any of the above was unclear, we planned to contact authors of the original reports to provide further details.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-08-28 08:53:59 +0100" MODIFIED_BY="Sonja L Henderson">
<P>Two review authors independently assessed risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Any disagreement was resolved by discussion or by involving a third assessor.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Random sequence generation (checking for possible selection bias)</HEADING>
<P>We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We assessed the method as:</P>
<UL>
<LI>low risk of bias (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>We described for each included study the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>high risk of bias (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.1) Blinding of participants and personnel (checking for possible performance bias)</HEADING>
<P>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding was unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low, high or unclear risk of bias for participants;</LI>
<LI>low, high or unclear risk of bias for personnel.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.2) Blinding of outcome assessment (checking for possible detection bias)</HEADING>
<P>We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed methods used to blind outcome assessment as:</P>
<UL>
<LI>low, high or unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data)</HEADING>
<P>We described for each included study, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the trial authors, we planned to re-include missing data in the analyses which we undertook.</P>
<P>We assessed methods as:</P>
<UL>
<LI>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups);</LI>
<LI>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; &#8216;as treated&#8217; analysis done with substantial departure of intervention received from that assigned at randomisation);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Selective reporting (checking for reporting bias)</HEADING>
<P>We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported);</LI>
<LI>high risk of bias (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</HEADING>
<P>We described for each included study any important concerns we had about other possible sources of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Overall risk of bias</HEADING>
<P>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <I>Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). With reference to (1) to (6) above, we planned to assess the likely magnitude and direction of the bias and whether we considered it is likely to impact on the findings. In future updates, we will explore the impact of the level of bias through undertaking sensitivity analyses - <I>see </I>Sensitivity analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of the quality of the evidence</HEADING>
<P>For this update we assessed the quality of the evidence using the GRADE approach (<LINK REF="REF-Schunemann-2009" TYPE="REFERENCE">Schunemann 2009</LINK>) in order to assess the quality of the body of evidence relating to the following outcomes for the main comparison.</P>
<OL>
<LI>Incidence of Rhesus D alloimmunisation during pregnancy</LI>
<LI>Incidence of Rhesus D alloimmunisation postpartum</LI>
<LI>Incidence of Rhesus D alloimmunisation in subsequent pregnancies</LI>
<LI>Incidence of positive Kleihauer test (at 32 to 35 weeks and at birth of a Rh-positive infant)</LI>
<LI>Neonatal morbidity (e.g. neonatal jaundice)</LI>
<LI>Adverse events attributed to anti-D treatment</LI>
</OL>
<P>We used GRADE profiler (<LINK REF="REF-GRADE-2014" TYPE="REFERENCE">GRADE 2014</LINK>) to import data from Review Manager 5.3 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>) in order to create a &#8217;Summary of findings&#8217; table. A summary of the intervention effect and a measure of quality for each of the above outcomes was produced using the GRADE approach. The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for each outcome. The evidence can be downgraded from 'high quality' by one level for serious (or by two levels for very serious) limitations, depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-05-09 04:26:10 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>For dichotomous data, we presented results as summary risk ratio with 95% confidence intervals.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>We planned to use the mean difference if outcomes were measured in the same way between trials. We planned to use the standardised mean difference to combine trials that measured the same outcome, but used different methods.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-08-11 10:01:28 +0100" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomised trials</HEADING>
<P>In future updates of this review, if we identify any eligible cluster-randomised trials. we plan to include them in the analyses along with individually-randomised trials. We plan to adjust their sample sizes using the methods described in the <I>Handbook </I>(Section 16.3.4) using an estimate of the intracluster correlation co-efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we use ICCs from other sources, we plan to report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster-randomised trials and individually-randomised trials, we plan to synthesise the relevant information. We consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit is considered to be unlikely.</P>
<P>We also plan to acknowledge heterogeneity in the randomisation unit and perform a subgroup analysis to investigate the effects of the randomisation unit.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cross-over trials</HEADING>
<P>We considered cross-over trials inappropriate for this review question.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-08-11 10:01:28 +0100" MODIFIED_BY="Heather Maxwell">
<P>For included studies, we noted levels of attrition. In future updates, if more eligible studies are included, the impact of including studies with high levels of missing data in the overall assessment of treatment effect will be explored by using sensitivity analysis.</P>
<P>For all outcomes, we carried out analyses, as far as possible, on an intention-to-treat basis i.e. we attempted to include all participants randomised to each group in the analyses. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-08-11 10:01:35 +0100" MODIFIED_BY="Heather Maxwell">
<P>We assessed statistical heterogeneity in each meta-analysis using the Tau², I² and Chi² statistics. We regarded heterogeneity as substantial if an I² was greater than 30% and either the Tau² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity. Had we identified substantial heterogeneity (above 30%), we planned to explore it by pre-specified subgroup analysis.  
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-08-11 10:01:35 +0100" MODIFIED_BY="Heather Maxwell">
<P>In future updates, if there are 10 or more studies in the meta-analysis, we will investigate reporting biases (such as publication bias) using funnel plots. We will assess funnel plot asymmetry visually. If asymmetry is suggested by a visual assessment, we will perform exploratory analyses to investigate it.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-08-11 10:01:35 +0100" MODIFIED_BY="Heather Maxwell">
<P>We carried out statistical analysis using the Review Manager software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We used fixed-effect meta-analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where trials were examining the same intervention, and the trials&#8217; populations and methods were judged sufficiently similar.</P>
<P>If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical heterogeneity was detected, we used random-effects meta-analysis to produce an overall summary, if an average treatment effect across trials was considered clinically meaningful. The random-effects summary was treated as the average range of possible treatment effects and we have discussed the clinical implications of treatment effects differing between trials. If the average treatment effect had not been clinically meaningful, we would not have combined trials. Where we used random-effects analyses, the results have been presented as the average treatment effect with 95% confidence intervals, and the estimates of Tau² and I².</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-08-11 10:01:41 +0100" MODIFIED_BY="Heather Maxwell">
<P>If we had identified substantial heterogeneity, we planned to investigate it using subgroup analyses and sensitivity analyses. We planned to consider whether an overall summary was meaningful, and if it was, use random-effects analysis to produce it.</P>
<P>If possible, we planned to carry out subgroup analysis considering aspects of the regimen for administration.</P>
<OL>
<LI>Timing of administration (e.g. single 1500 IU dose at 28 weeks versus 500 to 625 IU doses at 28 and 32 weeks)</LI>
<LI>Route of administration (intramuscular versus intravenous)</LI>
<LI>Dose administered</LI>
</OL>
<P>We planned to use only the primary outcomes in subgroup analysis. We were able to perform subgroup analysis for primary outcomes by dose administered only.</P>
<P>We assessed subgroup differences by interaction tests available within RevMan (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). In future updates, if more trials are included, we will report the results of subgroup analyses quoting the Chi² statistic and P value, and the interaction test I² value.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-08-11 10:01:47 +0100" MODIFIED_BY="Heather Maxwell">
<P>We planned to carry out sensitivity analyses to explore the effect of adequacy of allocation concealment (including quasi-randomisation) (selection bias) and other risk of bias components (including high attrition rates and attrition bias), by excluding those studies rated as 'high risk of bias' for these components. We would have restricted this to the primary outcomes. However, due to the paucity of data, sensitivity analyses were not possible in this version of the review.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-08-11 10:02:31 +0100" MODIFIED_BY="Heather Maxwell">
<STUDY_DESCRIPTION MODIFIED="2015-08-11 10:01:55 +0100" MODIFIED_BY="Heather Maxwell">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2015-08-11 10:01:55 +0100" MODIFIED_BY="Heather Maxwell">
<P>The updated search of the Cochrane Pregnancy and Childbirth Group's Trials Register found one ongoing trial (<LINK REF="STD-ACTRN12613000661774" TYPE="STUDY">ACTRN12613000661774</LINK>).</P>
<P>We previously included two trials (<LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK>; <LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK>), excluded one paper (<LINK REF="STD-Ismail-2002" TYPE="STUDY">Ismail 2002</LINK>), and found one ongoing trial (<LINK REF="STD-CTRI_x002f_2008_x002f_091_x002f_000157" TYPE="STUDY">CTRI/2008/091/000157</LINK>).</P>
<P>
<LINK REF="STD-ACTRN12613000661774" TYPE="STUDY">ACTRN12613000661774</LINK> intends to recruit 300 women and compare a single dose (1500 international units (IU) Rh(D)) at 28 weeks' gestation with routine treatment (625 IU Rh(D) Immunoglobin at 28 and 34 weeks) and was scheduled to start recruiting in May 2013, while <LINK REF="STD-CTRI_x002f_2008_x002f_091_x002f_000157" TYPE="STUDY">CTRI/2008/091/000157</LINK> is recorded as not yet recruiting but intends to compare a single dose of 1500 IU Rh(D) with no intervention in 100 women.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-08-11 10:01:55 +0100" MODIFIED_BY="Heather Maxwell">
<P>Two trials of anti-D immunoglobulin met our inclusion criteria, one from France (<LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK>), and one from the UK (<LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK>). Both trials compared routine antenatal anti-D prophylaxis with no anti-D prophylaxis, and neither study used a placebo.</P>
<P>
<LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK> recruited 1969 Rh-negative pregnant women without anti-D antibodies who attended antenatal clinics in the Paris region. Of the 1882 women with results available, 1450 were primigravid and 432 were multigravid. These women gave birth to 599 Rh-positive babies in the anti-D group and 590 Rh-positive babies in the control group.</P>
<P>
<LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK> recruited 2541 Rh-negative primigravidae; 1273 to the control group and 1268 to the treatment group. No further data were available for 469 women (205 in the control group and 264 in the treatment group). A further 52 women allocated to the treatment group did not receive both doses of anti-D, leaving 2020 women with results available for analysis. Of these women, 1108 gave birth to Rh-positive infants and were tested at the time of birth (595 in the control group and 513 in the treatment group); and 72 women with Rh-positive babies were not tested for anti-D at the time of the birth.</P>
<P>
<LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK> administered 100 µg (500 IU) anti-D at 28 and 34 weeks' gestation (total dose of 200 µg). <LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK> administered 50 µg (250 IU) anti-D at 28 and 34 weeks' gestation (total dose of 100 µg).</P>
<P>For further details of the two included studies, see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-08-13 12:58:31 +0100" MODIFIED_BY="[Empty name]">
<P>One paper was excluded (this was a plan for a trial, which is not proceeding at this stage, see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-08-11 10:02:10 +0100" MODIFIED_BY="Heather Maxwell">
<P>Summaries for the risk of bias of the included studies are given in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2015-05-02 06:47:10 +0100" MODIFIED_BY="[Empty name]">
<P>In the <LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK> trial, women were allocated to the two treatment groups by even or uneven year of birth, and thus the trial was judged to be at a high risk of selection bias. In <LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK>, no detail was provided regarding the random sequence generation, and whilst sealed envelopes were used to conceal allocation, no detail was provided regarding how the envelopes were numbered (i.e. if they were numbered consecutively), and if they were opaque, and thus selection bias was judged to be unclear.</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-05-02 06:47:15 +0100" MODIFIED_BY="[Empty name]">
<P>In both trials (<LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK>; <LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK>), no placebo was used in the control group, and no further details were provided regarding blinding of the trial personnel or outcome assessors. It was considered unclear as to whether the objectively measured outcomes would have been affected by a lack of blinding. Therefore, both trials were judged to be at an unclear risk of performance bias and detection bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-06-15 15:49:29 +0100" MODIFIED_BY="Nancy  Medley">
<P>Outcome data at the time of birth were not available for 4.4% (87/1969) of women who entered the French trial (<LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK>) and for more than 23% (593/2541) of women in the UK trial (<LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK>); with more losses to follow-up in the treatment group (335/1268; 26%) than the control group (258/1273; 20%). In the <LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK> trial, additional women were lost to follow-up at two to 12 months, leaving only 940 of the 1189 women who gave birth to a Rh-positive baby available for analysis for these outcomes. </P>
<P>In <LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK> an intention-to-treat analysis was possible for some outcomes, but this was not the case for <LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK>. Both trials were judged to be at high risk of attrition bias due to incomplete outcome data.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-08-11 10:02:10 +0100" MODIFIED_BY="Heather Maxwell">
<P>All outcome measures reported appear to have been pre-specified in the <LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK> trial, and it was thus judged to be at a low risk of selective reporting. In <LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK>, a number of outcomes that may have been expected were not reported, including for example, positive Kleihauer during pregnancy/delivery/postpartum and neonatal morbidity, and thus the trial was judged to be at an unclear risk of selective reporting. Neither trial reported adverse effects related to treatment.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2012-11-14 05:07:09 +0000" MODIFIED_BY="[Empty name]">
<P>No other obvious source of bias for the included studies was apparent.</P>
<P>Overall risk of bias was judged to be high for 
<LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK>
 and unclear for 
<LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK>.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-08-11 10:02:31 +0100" MODIFIED_BY="Heather Maxwell">
<P>See: <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>
</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Incidence of Rhesus D alloimmunisation during pregnancy; postpartum; and in subsequent pregnancies</HEADING>
<P>When women received anti-D at 28 and 34 weeks' gestation, the data pooled over both trials (<LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK>; <LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK>) did not reveal a clear difference between anti-D and no anti-D in the incidence of Rheus D alloimmunisation, during pregnancy (risk ratio (RR) 0.42, 95% confidence Interval (CI) 0.15 to 1.17; two trials, 3902 women; GRADE: <I>low quality evidence</I>) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), after the birth of a Rh-positive infant (RR 0.42, 95% CI 0.15 to 1.17; two trials, 2297 women) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), or within 12 months after birth of a Rh-positive infant (average RR 0.39, 95% CI 0.10 to 1.62; two trials, 2048 women; GRADE: <I>low quality evidence</I>) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). The moderate heterogeneity (I² = 39%) in the latter result may partly reflect the different doses used in the two randomised controlled trials, although the interaction test did not reveal a clear subgroup difference based on dose of anti-D (see below). <LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK> also reported on the incidence of Rhesus D alloimmunisation at two to 12 months following birth for primigravidae only, and did not find a clear difference between groups (RR: 0.11, 95% CI 0.01 to 2.04; 722 women) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>)</P>
<P>Neither of the two trials reported Rhesus D alloimmunisation in a subsequent pregnancy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analyses</HEADING>
<P>The subgroup analyses for dose of anti-D treatment have been integrated into the main structure of the graphs (Analysis 1) and comments relating to these subgroups have been made below.</P>
<P>The interaction tests, considering dose of anti-D treatment administered (100 µg (<LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK>) versus 50 µg at 28 and 34 weeks (<LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK>)) did not reveal any clear subgroup differences for any of the primary outcomes: immunisation during pregnancy (Chi²: 1.12; P: 0.29; I²: 10.4%) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), after birth of a Rh-positive infant (Chi ²: 1.25; P: 0.26; I²:20.3%) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) or within 12 months after birth of a Rh-positive infant (Chi²: 1.59; P: 0.21; I²: 37.0%) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>We were unable to perform other planned subgroup analyses (based on route of administration or timing of administration) or sensitivity analyses due to paucity of data.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Incidence of positive Kleihauer test</HEADING>
<P>In <LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK>, a positive Kleihauer result was found less commonly during pregnancy at 32 to 35 weeks (RR 0.60, 95% CI 0.41 to 0.88; 1884 women; GRADE: <I>low quality evidence</I>) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>), and after the birth of a Rh-positive infant (RR 0.60, 95% CI 0.46 to 0.79; 1189; GRADE: <I>low quality</I> <I>evidence</I>) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>) in the group of women treated at 28 and 34 weeks' gestation with anti-D, compared with the group of women who received no anti-D. After the birth of a Rh-positive infant, no clear difference between groups was shown however for the number of women with a Kleihauer result greater than one in 10,000 (RR 0.95, 95% CI 0.59 to 1.54; 1189 women) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Neonatal morbidity in current or subsequent pregnancies</HEADING>
<P>
<LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK> reported on neonatal jaundice. There was only one case in the group of neonates whose mothers had received anti-D, and three cases in the group of neonates born to mothers who received no anti-D (RR 0.26, 95% CI 0.03 to 2.30; 1882 neonates; GRADE: <I>very low quality</I> <I>evidence</I>) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
<P>Neither of the trials reported on any other outcomes relating to neonatal morbidity in current or subsequent pregnancies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events attributed to anti-D treatment</HEADING>
<P>Neither of the two trials reported on adverse effects related to treatment.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-08-11 10:02:39 +0100" MODIFIED_BY="Heather Maxwell">
<SUMMARY_OF_RESULTS MODIFIED="2015-08-11 10:02:39 +0100" MODIFIED_BY="Heather Maxwell">
<P>While a policy of routine antenatal prophylaxis with anti-D is unlikely to confer benefit or improve outcome in the current pregnancy, fewer women are likely to have Rhesus D antibodies in a subsequent pregnancy. As <LINK REF="REF-Chilcott-2002" TYPE="REFERENCE">Chilcott 2002</LINK> points out, the clinical benefit sought is the avoidance of haemolytic disease in subsequent babies; if the mother "has a RhD-positive infant <I>and</I> she would have been sensitised, <I>and </I>she goes on to have a further infant who is also Rh-D positive".</P>
<P>The quantity of available evidence to answer such an important question of policy was disappointingly low and there was a moderate to high risk of bias in the included studies. We included only two studies in this review, with a total of over 4500 women; one trial was quasi-randomised.</P>
<P>The reduction in the risk of alloimmunisation seen in this review in the <LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK> trial for Rh-negative women with a Rh-positive baby from about 1% to 0.2% with anti-D, however, is consistent with the findings of two non-randomised community studies reported in <LINK REF="REF-Chilcott-2002" TYPE="REFERENCE">Chilcott 2002</LINK> where the sensitisation rate was reduced from 0.95% to 0.35%. From these figures, Chilcott has calculated that 278 women would need to be treated antenatally with anti-D to avoid one case of sensitisation (based on all Rh-negative women; all will require treatment, since the 60% of women with Rh-positive babies would not yet be identified). Based on the findings of this review, the number needed to treat to benefit would be slightly lower, at 213 women.</P>
<P>Use of a smaller dose of anti-D (50 µg or 250 international units (IU)) in <LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK> at similar gestational ages failed to show any benefit. Women in the intervention and the control groups in both trials also received anti-D after the birth of a Rh-positive baby.</P>
<P>Anti-D does not appear to be harmful to the fetus, although there is a theoretical risk of passive anti-D in the mother causing fetal anaemia (<LINK REF="REF-Chilcott-2002" TYPE="REFERENCE">Chilcott 2002</LINK>). In 1994, batches of anti-D used in Ireland in 1977 and 1978 were found to be contaminated with hepatitis C virus, but additional safety features were introduced and no further instances of transmission of infectious disease have been reported (<LINK REF="REF-National-Blood-2003" TYPE="REFERENCE">National Blood 2003</LINK>). Neonatal jaundice was the only outcome relating to neonatal morbidity reported in the <LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK> trial, with no difference observed between groups. Neither of the trials reported on adverse effects related to anti-D treatment.</P>
<P>The costs of prophylaxis need to be considered against the cost of antenatal monitoring and treatment of any affected infant whose mother develops antibodies. The National Institute for Health and Clinical Excellence (NICE) in the UK has suggested that universal routine antenatal anti-D prophylaxis to prevent sensitisation, fetal loss and fetal morbidity is a cost-effective approach (<LINK REF="REF-NHS-2011" TYPE="REFERENCE">NHS 2011</LINK>).</P>
<P>Although the evidence for postpartum prophylaxis is stronger (as more studies of higher quality have been completed), antenatal prophylaxis is also likely to decrease the number of sensitisations, without adverse effects and may be considered to be complementary to postpartum prophylaxis.</P>
<P>The decision to implement a policy of antenatal prophylaxis may also be influenced by the availability of anti-D. In some countries, supplies of anti-D gammaglobulin are limited and, on occasions, temporarily exhausted. Before local adoption of a programme of anti-D prophylaxis in pregnancy, consideration would need to be given as to how to maintain an adequate supply of anti-D gammaglobulin for women in more urgent need. In many countries, including the UK and Australia, guidelines now advise routine universal antenatal anti-D prophylaxis (<LINK REF="REF-RCOG-2011" TYPE="REFERENCE">RCOG 2011</LINK>; <LINK REF="REF-RANZCOG-2004" TYPE="REFERENCE">RANZCOG 2004</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-09-10 10:33:06 +0100" MODIFIED_BY="[Empty name]">
<P>This review is limited with the inclusion of only two trials (<LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK>; <LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK>), that did not report on immunisation in subsequent pregnancies, important secondary review outcomes including neonatal morbidity (<LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK> reported only neonatal jaundice), or maternal adverse effects related to the anti-D treatment. We were unable to perform subgroup analyses based on timing, number of treatments required, and on route of administration, due to the paucity of data.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-07-07 06:29:46 +0100" MODIFIED_BY="[Empty name]">
<P>The two trials included in the review (with over 4500 women) were judged to be at a moderate to high risk of bias overall. The <LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK> trial was quasi-randomised, and thus at high risk of selection bias; the <LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK> trial did not clearly detail its selection methods. Neither trial used a placebo, and both trials had high rates of attrition.</P>
<P>We used the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach to assess evidence for pre-specified outcomes; results ranged from very low quality (neonatal jaundice) to low quality (immunisation during pregnancy; immunisation up to 12 months after birth of a Rh-positive infant; positive Kleihauer test at 32 to 35 weeks, and at the birth of a Rh-positive infant). There was no available evidence regarding incidence of Rhesus D alloimmunisation in subsequent pregnancies, or regarding adverse effects associated with anti-D treatment. Please see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-05-06 06:13:39 +0100" MODIFIED_BY="[Empty name]">
<P>The evidence for this review has been derived from trials identified through a detailed search process. It is possible (but unlikely) that additional trials assessing routine anti-D prophylaxis in pregnancy have been published but not identified. It is also possible that other studies have been conducted but not published. Should such studies be identified, we will include them in future updates of this review. Data from <LINK REF="STD-Huchet-1987" TYPE="STUDY">Huchet 1987</LINK> was obtained from a translation of the paper.</P>
</POTENTIAL_BIASES>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-08-11 10:03:09 +0100" MODIFIED_BY="Heather Maxwell">
<IMPLICATIONS_PRACTICE MODIFIED="2015-08-11 10:03:09 +0100" MODIFIED_BY="Heather Maxwell">
<P>In Rh-negative women carrying a Rh-positive baby, the risk of Rhesus D alloimmunisation during or immediately after a first pregnancy is about 1%. Administration of 100 µg (500 international units (IU)) anti-D at 28 and 34 weeks' gestation to women in their first pregnancy may reduce this risk to about 0.2% without, to date, any observed adverse effects. Although such a policy generally will not confer benefit or improve outcome in the current pregnancy, fewer women are likely to have Rhesus D antibodies in any subsequent pregnancy.</P>
<P>In adopting such a policy, costs of prophylaxis versus the costs of care for women who become sensitised and their affected infants need to be considered, along with local adequacy of supply of anti-D gammaglobulin.</P>
<P>Another Cochrane review has shown that postpartum administration of anti-D gammaglobulin is effective as prophylaxis against Rhesus D alloimmunisation (<I>see</I> review on anti-D prophylaxis postpartum, <LINK REF="REF-Crowther-1997" TYPE="REFERENCE">Crowther 1997</LINK>).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-11-14 05:15:29 +0000" MODIFIED_BY="Rosemary D McBain">
<P>Further trials are warranted to determine the optimal timing, number of treatments, and effective dosage of anti-D administration in pregnancy. The cost-effectiveness of such a policy requires further evaluation. However, one of the most important areas to investigate is the effect of antenatal anti-D on subsequent pregnancies. The move towards more universal antenatal anti-D policies may provide an environment for more robust research to be carried out.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-07-08 14:05:46 +0100" MODIFIED_BY="Leanne V Jones">
<P>We thank Emily Bain for her assistance with this most recent update of the review.</P>
<P>For the first version of this review, we thank Professor Marc Keirse for his contributions, and Gill Gyte for her very helpful comments. We also thank Lynn Hampson and Denise Atherton for their help with the updates.</P>
<P>This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Pregnancy and Childbirth. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-06-19 13:14:46 +0100" MODIFIED_BY="Leanne V Jones">
<P>Caroline A Crowther contributed to the development of the protocol, identification and selection of trials for inclusion and the preparation of the text of the first publication of the review.</P>
<P>Rosie McBain, Caroline A Crowther and Philippa Middleton contributed to the earlier update and this update.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-09-02 14:06:34 +0100" MODIFIED_BY="[Empty name]">
<P>In this update, we have updated the methods to include the use of GRADE profiler (<LINK REF="REF-GRADE-2014" TYPE="REFERENCE">GRADE 2014</LINK>), which was used to import data from Review Manager 5.3 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>) in order to create a 'Summary of findings' table.</P>
<P>In the previous update of this review, we updated the methods including the assessment of risk of bias. We separated the outcomes into primary and secondary outcomes, and added adverse effects attributed to treatment as a secondary outcome. We clarified that cluster trials, and cross-over trials would be excluded, that comparisons will be with no treatment or placebo or a different anti-D regimen.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-08-10 18:01:47 +0100" MODIFIED_BY="Heather Maxwell">
<STUDIES MODIFIED="2015-05-09 04:33:52 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-11-14 05:19:31 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Huchet-1987" MODIFIED="2012-11-14 05:19:31 +0000" MODIFIED_BY="[Empty name]" NAME="Huchet 1987" YEAR="1987">
<REFERENCE MODIFIED="2012-11-14 05:19:31 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[3679]&lt;/p&gt;" NOTES_MODIFIED="2012-11-14 05:19:31 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huchet J, Dallemagne S, Huchet C, Brossard Y, Larsen M, Parnet-Mathieu F</AU>
<TI>The antepartum use of anti-D immunoglobulin in rhesus negative women. Parallel evaluation of fetal blood cells passing through the placenta. The results of a multi-centre study carried out in the region of Paris</TI>
<SO>European Journal of Obstetrics, Gynecology, and Reproductive Biology</SO>
<YR>1987</YR>
<VL>16</VL>
<PG>101-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1995" NAME="Lee 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;[8841]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee D, Rawlinson VI</AU>
<TI>Multicentre trial of antepartum low-dose anti-D immunoglobulin</TI>
<SO>Transfusion Medicine</SO>
<YR>1995</YR>
<VL>5</VL>
<PG>15-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-05-06 06:19:20 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Ismail-2002" MODIFIED="2015-05-06 06:19:20 +0100" MODIFIED_BY="[Empty name]" NAME="Ismail 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ismail K, Kilby M, Alfirevic Z, Khan K, Whittle M</AU>
<TI>Prospective randomised trial of alloimmunisation management (PRAM)</TI>
<SO>Journal of Obstetrics and Gynaecology</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>2 Suppl</NO>
<PG>S33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-03-05 03:47:02 +0000" MODIFIED_BY="Rosemary D McBain"/>
<ONGOING_STUDIES MODIFIED="2015-05-09 04:33:52 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ACTRN12613000661774" MODIFIED="2015-05-09 04:32:20 +0100" MODIFIED_BY="[Empty name]" NAME="ACTRN12613000661774" YEAR="2014">
<REFERENCE MODIFIED="2015-05-09 04:32:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ACTRN12613000661774</AU>
<TI>Detectability of anti-D and compliance in two regimens</TI>
<SO>https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12613000661774</SO>
<YR>(accessed 6 May 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ACTRN12613000661774"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CTRI_x002f_2008_x002f_091_x002f_000157" MODIFIED="2015-05-09 04:33:52 +0100" MODIFIED_BY="[Empty name]" NAME="CTRI/2008/091/000157" YEAR="2009">
<REFERENCE MODIFIED="2015-05-09 04:33:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>CTRI/2008/091/000157</AU>
<TI>A clinical trial to study the effect of injection anti D administered during pregnancy for Rh negative mothers</TI>
<SO>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=172</SO>
<YR>(accessed 6 May 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-11-14 21:49:55 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-11-14 21:49:55 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="CTRI/2008/091/000157"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-08-10 18:01:47 +0100" MODIFIED_BY="Heather Maxwell">
<ADDITIONAL_REFERENCES MODIFIED="2015-05-09 04:34:13 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bishler-2003" MODIFIED="2012-08-03 01:52:16 +0100" MODIFIED_BY="Rosemary D McBain" NAME="Bishler 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bishler J, Schondorfer G, Pabst G, Andresen I</AU>
<TI>Pharmacokinetics of anti-D IgG in pregnant Rh-D negative women</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>2003</YR>
<VL>110</VL>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boruchov-2005" MODIFIED="2012-08-14 06:13:01 +0100" MODIFIED_BY="Rosemary D McBain" NAME="Boruchov 2005" TYPE="JOURNAL_ARTICLE">
<AU>Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW</AU>
<TI>Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>2005</YR>
<VL>115</VL>
<PG>2914-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bowman-1965" MODIFIED="2012-05-12 06:39:44 +0100" MODIFIED_BY="Rosemary D McBain" NAME="Bowman 1965" TYPE="JOURNAL_ARTICLE">
<AU>Bowman JM, Pollock JM</AU>
<TI>Amniotic fluid spectrophotometry and early delivery in the management of erythroblastosis fetalis</TI>
<SO>Pediatrics</SO>
<YR>1965</YR>
<VL>35</VL>
<PG>815</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bowman-1996" MODIFIED="2012-08-14 06:19:46 +0100" MODIFIED_BY="Rosemary D McBain" NAME="Bowman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bowman JM</AU>
<TI>Hemolytic disease of the newborn</TI>
<SO>Vox Sanguinis</SO>
<YR>1996</YR>
<VL>70</VL>
<PG>62-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chilcott-2002" MODIFIED="2008-10-29 10:49:49 +0000" MODIFIED_BY="[Empty name]" NAME="Chilcott 2002" TYPE="BOOK">
<AU>Chilcott J, Lloyd Jones M, Wight J, Forman K, Wray J, Beverley C</AU>
<SO>A review of the clinical effectiveness and cost effectiveness of routine anti-D prophylaxis for pregnant women who are Rhesus (RhD) negative</SO>
<YR>2002</YR>
<PB>National Institute of Clinical Excellence</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chown-1954" MODIFIED="2013-01-13 12:22:54 +0000" MODIFIED_BY="Rosemary D McBain" NAME="Chown 1954" TYPE="JOURNAL_ARTICLE">
<AU>Chown B</AU>
<TI>Anaemia from bleeding of the fetus into the mother&#8217;s circulation</TI>
<SO>Lancet</SO>
<YR>1954</YR>
<VL>263</VL>
<NO>6824</NO>
<PG>1213</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Contreras-1998" MODIFIED="2008-10-29 10:49:49 +0000" MODIFIED_BY="[Empty name]" NAME="Contreras 1998" TYPE="JOURNAL_ARTICLE">
<AU>Contreras M</AU>
<TI>The prevention of Rh haemolytic disease of the fetus and newborn - general background</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1998</YR>
<VL>105</VL>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coopamah-2003" MODIFIED="2013-01-13 12:23:25 +0000" MODIFIED_BY="Rosemary D McBain" NAME="Coopamah 2003" TYPE="JOURNAL_ARTICLE">
<AU>Coopamah MD, Freeman J, Semple JW</AU>
<TI>Anti-D initially stimulates an Fc-dependant leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonist</TI>
<SO>Blood</SO>
<YR>2003</YR>
<VL>102</VL>
<PG>2862-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Craig-1998" MODIFIED="2013-01-13 12:23:41 +0000" MODIFIED_BY="Rosemary D McBain" NAME="Craig 1998" TYPE="JOURNAL_ARTICLE">
<AU>Craig JS, McClure BG, Tubman TRJ</AU>
<TI>Services should be centralised for pregnancies affected by RhD haemolytic disease</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>316</VL>
<PG>1611</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crowther-1997" MODIFIED="2012-06-07 02:32:25 +0100" MODIFIED_BY="Lynn Hampson" NAME="Crowther 1997" TYPE="COCHRANE_REVIEW">
<AU>Crowther C, Middleton P</AU>
<TI>Anti-D administration after childbirth for preventing Rhesus alloimmunisation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1997</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-07-05 14:32:31 +0100" MODIFIED_BY="Lynn Hampson">
<IDENTIFIER MODIFIED="2011-07-05 14:32:31 +0100" MODIFIED_BY="Lynn Hampson" TYPE="DOI" VALUE="10.1002/14651858.CD000021"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Davey-1979" MODIFIED="2008-10-29 10:49:49 +0000" MODIFIED_BY="[Empty name]" NAME="Davey 1979" TYPE="JOURNAL_ARTICLE">
<AU>Davey MG, Zipursky A</AU>
<TI>Proceedings of the McMaster Rh Conference</TI>
<SO>Vox Sanguinis</SO>
<YR>1979</YR>
<VL>36</VL>
<PG>50-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Engelfriet-2003" MODIFIED="2012-08-14 06:13:40 +0100" MODIFIED_BY="Rosemary D McBain" NAME="Engelfriet 2003" TYPE="JOURNAL_ARTICLE">
<AU>Engelfriet CP, Reesink HW, Judd WJ, Ulander VM, Kuosmanen M, Koskinen S, et al</AU>
<TI>Current status of immunoprophylaxis with anti-D immunoglobin</TI>
<SO>Vox Sanguinis</SO>
<YR>2003</YR>
<VL>85</VL>
<NO>4</NO>
<PG>328-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADE-2014" MODIFIED="2015-05-09 04:34:13 +0100" MODIFIED_BY="[Empty name]" NAME="GRADE 2014" TYPE="OTHER">
<TI>McMaster University.GRADEpro. [Computer program on www.gradepro.org]</TI>
<SO>Version [2014]. McMaster University, 2014.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gravenhorst-1989" MODIFIED="2013-01-13 12:24:54 +0000" MODIFIED_BY="[Empty name]" NAME="Gravenhorst 1989" TYPE="BOOK_SECTION">
<AU>Gravenhorst JB</AU>
<TI>Rhesus isoimmunisation</TI>
<SO>Effective Care in Pregnancy and Childbirth</SO>
<YR>1989</YR>
<PG>565-77</PG>
<ED>Chalmers I, Enkin MW, Keirse MJNC</ED>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gunson-1976" MODIFIED="2012-08-03 01:53:33 +0100" MODIFIED_BY="Rosemary D McBain" NAME="Gunson 1976" TYPE="JOURNAL_ARTICLE">
<AU>Gunson HH, Stratton F, Philips PK</AU>
<TI>The primary Rho(D) immune response in male volunteers</TI>
<SO>British Journal of Haematology</SO>
<YR>1976</YR>
<VL>32</VL>
<PG>317-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-06-07 03:34:30 +0100" MODIFIED_BY="Rosemary D McBain" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2004" MODIFIED="2012-08-14 06:15:54 +0100" MODIFIED_BY="Rosemary D McBain" NAME="Jones 2004" TYPE="JOURNAL_ARTICLE">
<AU>Jones ML, Wray J, Wright J, Chilcott J, Forman K, Tappenden P, et al</AU>
<TI>A review of the clinical effectiveness of routine antenatal anti-D prophylaxis for rhesus-negative women who are pregnant</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>2004</YR>
<VL>111</VL>
<PG>892-902</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kumpel-2001" MODIFIED="2012-11-13 22:22:34 +0000" MODIFIED_BY="Rosemary D McBain" NAME="Kumpel 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kumpel BM, Elson CJ</AU>
<TI>Mechanism of anti-D mediated immune suppression - a paradox awaiting resolution?</TI>
<SO>Trends in Immunology</SO>
<YR>2001</YR>
<VL>22</VL>
<PG>26-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kumpel-2002" MODIFIED="2012-08-03 01:54:25 +0100" MODIFIED_BY="Rosemary D McBain" NAME="Kumpel 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kumpel BM</AU>
<TI>On the mechanism of tolerance to the Rh D antigen mediated by passive anti-D (Rh D prophylaxis)</TI>
<SO>Immunology Letters</SO>
<YR>2002</YR>
<VL>82</VL>
<PG>67-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liumbruno-2010" MODIFIED="2013-01-13 12:25:40 +0000" MODIFIED_BY="Rosemary D McBain" NAME="Liumbruno 2010" TYPE="JOURNAL_ARTICLE">
<AU>Liumbruno GM, D&#8217;Alessandro A, Rea F, Piccinini V, Catalano L, Calizzani G, et al</AU>
<TI>The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation</TI>
<SO>Blood Transfusion</SO>
<YR>2010</YR>
<VL>8</VL>
<NO>1</NO>
<PG>8-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mackenzie-2006" MODIFIED="2012-08-14 06:16:45 +0100" MODIFIED_BY="Rosemary D McBain" NAME="Mackenzie 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mackenzie IZ, Roseman F, Findlay J, Thompson K, Jackson E, Scott J, et al</AU>
<TI>The kinetics of routine antenatal prophylactic intramuscular injections of polyclonal anti-D immunoglobin</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>2006</YR>
<VL>113</VL>
<PG>97-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-National-Blood-2003" MODIFIED="2008-10-29 10:49:49 +0000" MODIFIED_BY="[Empty name]" NAME="National Blood 2003" TYPE="BOOK">
<AU>National Blood Authority</AU>
<SO>Guidelines on the prophylactic use of Rh D immunoglobulin (anti-D) in obstetrics</SO>
<YR>2003</YR>
<PB>NHMRC</PB>
<CY>Canberra, ACT</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NHS-2011" MODIFIED="2012-11-13 22:32:06 +0000" MODIFIED_BY="Rosemary D McBain" NAME="NHS 2011" TYPE="OTHER">
<AU>NHS National Institute for Health and Clinical Excellece</AU>
<TI>Routine antenatal anti-D prophylaxis for women who are rhesus D negative: Review of NICE technology appraisal guidance 41</TI>
<SO>http://www.nice.org.uk/</SO>
<YR>(accessed 14 November 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RANZCOG-2004" MODIFIED="2012-11-14 05:19:06 +0000" MODIFIED_BY="[Empty name]" NAME="RANZCOG 2004" TYPE="OTHER">
<AU>Royal Australian and New Zealand College of Obstetricians and Gynaecologists</AU>
<TI>Guidelines for the use of RhD immunoglobulin (Anti-D) in obstetrics in Australia</TI>
<SO>www.ranzcog.edu.au/</SO>
<YR>(accessed 2 November 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RCOG-2011" MODIFIED="2012-11-14 05:19:14 +0000" MODIFIED_BY="Rosemary D McBain" NAME="RCOG 2011" TYPE="OTHER">
<AU>Royal College of Obstetricians and Gynaecologists</AU>
<TI>The use of anti-D immunoglobulin for rhesus D prophylaxis. Green-top guideline</TI>
<SO>http://www.rcog.org.uk/</SO>
<YR>(accessed 14 November 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2014-11-17 11:09:30 +0000" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schunemann-2009" MODIFIED="2014-11-17 11:08:50 +0000" MODIFIED_BY="[Empty name]" NAME="Schunemann 2009" TYPE="JOURNAL_ARTICLE">
<AU>Schunemann HJ</AU>
<TI>GRADE: from grading the evidence to developing recommendations. A description of the system and a proposal regarding the transferability of the results of clinical research to clinical practice</TI>
<TO>GRADE: Von der Evidenz zur Empfehlung. Beschreibung des Systems und Losungsbeitrag zur Ubertragbarkeit von Studienergebnissen</TO>
<SO>Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen</SO>
<YR>2009</YR>
<VL>103</VL>
<NO>6</NO>
<PG>391-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stern-1961" MODIFIED="2008-10-29 10:49:49 +0000" MODIFIED_BY="[Empty name]" NAME="Stern 1961" TYPE="JOURNAL_ARTICLE">
<AU>Stern K, Goodman HS, Berger M</AU>
<TI>Experimental isoimmunisation to hemoantigens in man</TI>
<SO>Journal of Immunology</SO>
<YR>1961</YR>
<VL>87</VL>
<PG>189</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turner-2012" MODIFIED="2013-01-13 12:28:41 +0000" MODIFIED_BY="Rosemary D McBain" NAME="Turner 2012" TYPE="JOURNAL_ARTICLE">
<AU>Turner RM, Lloyd-Jones M, Anumba DO, Smith GC, Spiegelhalter DJ, Squires H, et al</AU>
<TI>Routine antenatal anti-d prophylaxis in women who are rh(d) negative: meta-analyses adjusted for differences in study design and quality</TI>
<SO>PLoS ONE</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>2</NO>
<PG>e30711</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zipursky-1967" MODIFIED="2008-10-29 10:49:49 +0000" MODIFIED_BY="[Empty name]" NAME="Zipursky 1967" TYPE="JOURNAL_ARTICLE">
<AU>Zipursky A, Israels LG</AU>
<TI>The pathogenesis and prevention of Rh immunization</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1967</YR>
<VL>97</VL>
<PG>1245-57</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-08-10 18:01:47 +0100" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Crowther-1999" MODIFIED="2015-08-10 18:01:47 +0100" MODIFIED_BY="Heather Maxwell" NAME="Crowther 1999" TYPE="COCHRANE_REVIEW">
<AU>Crowther CA, Middleton P</AU>
<TI>Anti-D administration in pregnancy for preventing Rhesus alloimmunisation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-06-07 03:39:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-06-07 03:39:39 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000020"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Crowther-2013" MODIFIED="2015-08-10 18:01:01 +0100" MODIFIED_BY="Heather Maxwell" NAME="Crowther 2013" TYPE="COCHRANE_REVIEW">
<AU>Crowther CA, Middleton P, McBain RD</AU>
<TI>Anti-D administration in pregnancy for preventing Rhesus alloimmunisation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-11-17 11:12:39 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-17 11:12:39 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000020.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-08-10 18:11:55 +0100" MODIFIED_BY="Heather Maxwell">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-08-10 18:10:31 +0100" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-08-10 18:10:31 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Huchet-1987">
<CHAR_METHODS MODIFIED="2012-06-07 01:28:27 +0100" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-16 11:55:59 +0100" MODIFIED_BY="[Empty name]">
<P>1969 women were randomised from January 1983 to June 1984.</P>
<P>
<B>Setting:</B> women were recruited from 23 maternity units in the Paris region, France.</P>
<P>
<B>Inclusion criteria:</B> women who were primipara and were Rh-negative.</P>
<P>
<B>Exclusion criteria: </B>none detailed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-08-10 18:10:31 +0100" MODIFIED_BY="Heather Maxwell">
<P>
<B>Treatment group (Anti-D) (n = 927)</B>
</P>
<P>Women received 2 anti-D immunoglobulin injections (100 µg by intramuscular injection (500 IU)) at 28 and 34 weeks' gestation, after blood samples had been taken.</P>
<P>
<B>Control group (no Anti-D) (n = 955)</B>
</P>
<P>No placebo was given.</P>
<P>In both groups, women who gave birth to a Rh-positive baby were administered postpartum (intravenously in almost all cases) anti-D immunoglobulin (100 µg), with possible re-treatment following review of fetal red blood cell test results.</P>
<P>1450 women were primigravid and 432 were multigravid.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-09 04:30:59 +0100" MODIFIED_BY="[Empty name]">
<P>Incidence of immunisation during pregnancy, immunisation at 2 to 12 months following pregnancy, positive Kleihauer during pregnancy, at delivery, or postpartum. Cost-effectiveness data also provided.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-02 05:50:42 +0000" MODIFIED_BY="[Empty name]">
<P>From the translation received for this manuscript, 1969 women began the study, with 1882 monitored until they went into labour.</P>
<P>The blood groups ABO and Rhesus D were determined using standard techniques.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-16 12:06:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-1995">
<CHAR_METHODS MODIFIED="2012-06-07 03:47:05 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-16 11:56:21 +0100" MODIFIED_BY="[Empty name]">
<P>2541 women were randomised.</P>
<P>
<B>Setting:</B> obstetric units throughout the UK.</P>
<P>
<B>Inclusion criteria:</B> Rh-negative primigravidae before 28 weeks' gestation.</P>
<P>
<B>Exclusion criteria:</B> any woman with anti-D other than passive found at a 28-week blood sample was excluded from the trial.</P>
<P>Women who had already received anti-D to cover a potentially sensitising event were not excluded - where such an event took place after 28 weeks, the patient received anti-D in the usual way.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-09 04:31:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment group (Anti-D) (n = 1268)</B>
</P>
<P>Women in the treatment group received 50 µg (250 IU) anti-D intramuscularly at 28 and 34 weeks' gestation (n = 952).</P>
<P>
<B>Control group (no Anti-D) (n = 1273)</B>
</P>
<P>No placebo was given.</P>
<P>Women in both groups "were considered for anti-D Ig in the normal way at delivery".</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-07 02:53:48 +0100" MODIFIED_BY="[Empty name]">
<P>Presence of anti-D at birth and 6 months postpartum (repeated if equivocal); also reported "potentially sensitizing events."</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-16 12:06:33 +0100" MODIFIED_BY="[Empty name]">
<P>Sample size needed to detect 5-fold reduction in sensitisation: 5200 women.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>IU: international units</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-08-03 01:43:57 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-08-03 01:43:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ismail-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-03 01:43:57 +0100" MODIFIED_BY="[Empty name]">
<P>This is only the plan for a trial. Trial not proceeding at this stage (Z Alfirevic, personal communication March 2004).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-03-05 03:47:02 +0000" MODIFIED_BY="Rosemary D McBain" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-08-10 18:11:55 +0100" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2015-06-16 11:57:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ACTRN12613000661774">
<CHAR_STUDY_NAME MODIFIED="2015-06-16 11:57:02 +0100" MODIFIED_BY="[Empty name]">
<P>Detectability of anti-D and compliance in two regimens.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-03-30 05:58:15 +0100" MODIFIED_BY="Rosemary D McBain">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-16 11:57:12 +0100" MODIFIED_BY="[Empty name]">
<P>Recruitment target: 300 women.</P>
<P>
<B>Setting: </B>King Edward Memorial Hospital, WA, Australia.</P>
<P>
<B>Inclusion criteria</B>: female, pregnant, aged over 18 years, with a negative antibody screen and no contraindication for anti-D intramuscular injection, such as previous anaphylaxis to immunoglobulin, isolated immunoglobulin A deficiency, or previously recorded endogenous anti-D antibodies.</P>
<P>
<B>Exclusion criteria</B>: aged less than 18 years at recruitment, non-pregnant, Rh-positive, allergy/adverse reaction to constituents of anti-D as per product information.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-09 04:31:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment group: </B>1500 IU Rh(D) immunoglobulin-VF at 28 weeks' gestation.</P>
<P>
<B>Control group: </B>625 IU Rh(D) immunoglobulin-VF at 28 and 34 weeks' gestation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-16 11:57:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes</B>: detectability of anti-D at delivery via standard detection practices employed at King Edward Memorial Hospital and proportion of women receiving doses at correct gestation via analysis of number of enrolments compared with the number and timing of doses delivered in each arm of the study.</P>
<P>
<B>Secondary outcomes</B>: risk factors for no detectable antibody at delivery via questionnaire and review of medical records, complication rates (obstetric and neonatal) via review of medical records and the total amount of anti-D used per participant.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-03-20 02:03:52 +0000" MODIFIED_BY="Rosemary D McBain">
<P>3/5/13</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-05-02 06:47:48 +0100" MODIFIED_BY="[Empty name]">
<P>A/Prof Craig E Pennell</P>
<P>School of Womens' and Infants' Health</P>
<P>University of Western Australia</P>
<P>35 Stirling Highway, Crawley, WA 6009</P>
<P>Phone: +61893401326</P>
<P>Email: craig.pennell@uwa.edu.au</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-03-05 03:47:02 +0000" MODIFIED_BY="Rosemary D McBain"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-08-10 18:11:55 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-CTRI_x002f_2008_x002f_091_x002f_000157">
<CHAR_STUDY_NAME MODIFIED="2015-06-16 11:57:41 +0100" MODIFIED_BY="[Empty name]">
<P>A clinical trial to study the effect of injection of anti-D administered during pregnancy for Rh-negative mothers.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-08-14 07:50:28 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-10 18:11:55 +0100" MODIFIED_BY="Heather Maxwell">
<P>Recruitment target: 100 women.</P>
<P>
<B>Setting:</B> Dr TMA Pai Rotary Hospital, Karkala, India.</P>
<P>
<B>Inclusion criteria:</B> all Rh-negative and indirect agglutinin test negative primigravida and un-sensitised multigravida who are willing to participate in the study.</P>
<P>
<B>Exclusion criteria: </B>all Rh-negative mothers with Rh-negative husbands. Indirect agglutination test positive.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-06-16 11:57:54 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment group: </B>antenatal administration of 300 µg (1500 IU) of Rh-D immunoglobulin.</P>
<P>
<B>Control group: </B>no intervention.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-16 11:58:03 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes: </B>incidence of immunisation during pregnancy at term, at delivery and at 6 months.</P>
<P>
<B>Secondary outcomes:</B> incidence of neonatal hyperbilirubinaemia, need for exchange transfusion, and need for phototherapy.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-06-16 11:58:08 +0100" MODIFIED_BY="[Empty name]">
<P>1/12/2008 on the trial registry however, the trial is listed as "not yet recruiting".</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-06-16 11:58:13 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Scientific queries:</B>
</P>
<P>Dr AP Manjunath</P>
<P>Associate Professor</P>
<P>Department of Obstetrics and Gynaecology</P>
<P>576104, India</P>
<P>Phone: 09845913140</P>
<P>Fax: 080257061</P>
<P>Email: manjunanth.ap@manipal.edu</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-08-13 13:01:59 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>IU: international units</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-08-10 18:09:34 +0100" MODIFIED_BY="Heather Maxwell">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-05-09 04:30:59 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-09 04:30:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huchet-1987">
<DESCRIPTION>
<P>Not detailed - women were allocated to groups on the basis of their birth year (even/odd).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-03 00:23:28 +0100" MODIFIED_BY="Rosemary D McBain" RESULT="UNKNOWN" STUDY_ID="STD-Lee-1995">
<DESCRIPTION>
<P>Generation of random sequence was not detailed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-08-03 00:23:29 +0100" MODIFIED_BY="Rosemary D McBain" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 01:28:23 +0100" MODIFIED_BY="Rosemary D McBain" RESULT="NO" STUDY_ID="STD-Huchet-1987">
<DESCRIPTION>
<P>As above. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-03 00:23:29 +0100" MODIFIED_BY="Rosemary D McBain" RESULT="UNKNOWN" STUDY_ID="STD-Lee-1995">
<DESCRIPTION>
<P>Quote - "sealed envelopes" were used; no further detail provided regarding how the envelopes were numbered, or whether they were opaque.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-08-03 00:23:30 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-03 00:23:27 +0100" MODIFIED_BY="Rosemary D McBain" RESULT="UNKNOWN" STUDY_ID="STD-Huchet-1987">
<DESCRIPTION>
<P>Blinding was not detailed, however considered unlikely in view of the intervention. The lack of blinding, however, may be considered unlikely to affect the objectively measured outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-03 00:23:30 +0100" MODIFIED_BY="Rosemary D McBain" RESULT="UNKNOWN" STUDY_ID="STD-Lee-1995">
<DESCRIPTION>
<P>Blinding was not detailed, however considered unlikely in view of the intervention. The lack of blinding, however, may be considered unlikely to affect the objectively measured outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-06-07 06:54:43 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-07 06:54:23 +0100" MODIFIED_BY="Rosemary D McBain" RESULT="UNKNOWN" STUDY_ID="STD-Huchet-1987">
<DESCRIPTION>
<P>As above. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-07 06:54:43 +0100" MODIFIED_BY="Rosemary D McBain" RESULT="UNKNOWN" STUDY_ID="STD-Lee-1995">
<DESCRIPTION>
<P>As above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-08-10 18:09:34 +0100" MODIFIED_BY="Heather Maxwell" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-08-10 18:08:32 +0100" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Huchet-1987">
<DESCRIPTION>
<P>From the translation received - 1969 women began the study, of those 1882 were monitored until they were in labour (the 87 women not followed up to birth were not accounted for).</P>
<P>In the control group, 2/957 women were excluded due to fetal-maternal haemorrhage, leaving 955 who were monitored until labour. Of these women, 590/955 gave birth to a Rh-positive baby, however 2 died at birth; 468 women were followed up postpartum (no reasons given for the 122 women not followed up postpartum). In the treatment group, 599/927 gave birth to a Rh-positive baby; 472 women were followed up postpartum (no reasons given for the 127 women not followed up postpartum).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-08-10 18:09:34 +0100" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Lee-1995">
<DESCRIPTION>
<P>1273 women were controls and 1268 were in the treatment group; no data were provided for 205 controls and 264 women from the treatment group (no details provided). In the control group, 649 women gave birth to Rh-positive infants (398 infants were Rh-negative; unknown for 21 infants). 1 additional woman was excluded from the control group after she was found to have immune anti-D at randomisation with a history of threatened abortion. Therefore, 648 women from the control group were included in the analysis. In the treatment group 532 women and infants were included in the analysis (393 infants were Rh-negative, and 52 women did not receive both doses of anti-D and these women were excluded from further analyses - unknown whether infants were Rh-positive/negative). Not an intention-to-treat analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-08-03 00:23:37 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 02:05:05 +0100" MODIFIED_BY="Rosemary D McBain" RESULT="YES" STUDY_ID="STD-Huchet-1987">
<DESCRIPTION>
<P>No clear evidence of selective reporting - outcome measures reported appear to have been pre-specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-03 00:23:37 +0100" MODIFIED_BY="Rosemary D McBain" RESULT="UNKNOWN" STUDY_ID="STD-Lee-1995">
<DESCRIPTION>
<P>Trial reported only presence of anti-D at birth and 6 months postpartum; a number of outcomes that may have been expected, such as positive Kleihauer during pregnancy/delivery/postpartum, or neonatal morbidity were not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-12-20 15:54:04 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-20 15:54:04 +0000" MODIFIED_BY="Rosemary D McBain" RESULT="YES" STUDY_ID="STD-Huchet-1987">
<DESCRIPTION>
<P>No obvious risk of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-14 07:38:42 +0100" MODIFIED_BY="Rosemary D McBain" RESULT="YES" STUDY_ID="STD-Lee-1995">
<DESCRIPTION>
<P>No other obvious sources of bias identified. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-08-10 18:14:55 +0100" MODIFIED_BY="Heather Maxwell">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-08-10 18:14:55 +0100" MODIFIED_BY="Heather Maxwell" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-08-10 18:14:42 +0100" MODIFIED_BY="Heather Maxwell">Anti-D administration in pregnancy compared with no treatment for pregnancy for preventing Rhesus alloimmunisation</TITLE>
<TABLE COLS="7" ROWS="19">
<TR>
<TD COLSPAN="7">
<P>
<B>Anti-D administration in pregnancy compared with no treatment for pregnancy for preventing Rhesus alloimmunisation</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>Rh-negative women without anti-D antibodies<BR/>
<B>Settings: </B>obstetric/maternity units<BR/>
<B>Intervention: </B>anti-D administration in pregnancy<BR/>
<B>Comparison: </B>no treatment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No treatment</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Anti-D administration in pregnancy</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Incidence of Rhesus D alloimmunisation during pregnancy</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.42<BR/>(0.15 to 1.17)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>3902<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>6 per 1000</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>3 per 1000<BR/>(1 to 8)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Incidence of Rhesus D alloimmunisation postpartum (at birth of Rh-positive infant and at follow-up (up to 12 months))</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.39<BR/>(0.10 to 1.62)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>2048<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>15 per 1000</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>6 per 1000<BR/>(2 to 24)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Incidence of Rhesus D alloimmunisation in a subsequent pregnancy</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>This outcome was not reported in the 2 included studies</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Incidence of positive Kleihauer test (at 32 to 35 weeks' gestation)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.60<BR/>(0.41 to 0.88)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>1884<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>70 per 1000</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>42 per 1000<BR/>(29 to 62)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Incidence of positive Kleihauer test (at birth of a Rh-positive infant)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.60<BR/>(0.46 to 0.79)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>1189<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>202 per 1000</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>121 per 1000<BR/>(93 to 159)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Neonatal jaundice</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.26<BR/>(0.03 to 2.30)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>1882<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>VERY LOW <SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>4 per 1000</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1 per 1000<BR/>(0 to 10)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adverse events attributed to anti-D treatment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>This outcome was not reported in the 2 included studies</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the median control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI: </B>confidence interval;<B> RR</B>: risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality: </B>Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality: </B>Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality: </B>Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality: </B>We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Both studies contributing data had design limitations (-1).</P>
<P>
<SUP>2</SUP>Wide confidence intervals crossing the line of no effect (-1). We have not downgraded for few events or small sample size.</P>
<P>
<SUP>3</SUP>One study with serious design limitations (-2).</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-08-10 18:16:30 +0100" MODIFIED_BY="Heather Maxwell">
<COMPARISON ID="CMP-001" MODIFIED="2015-08-10 18:16:30 +0100" MODIFIED_BY="Heather Maxwell" NO="1">
<NAME>Anti-D administration in pregnancy</NAME>
<DICH_OUTCOME CHI2="1.1456508333733382" CI_END="1.1669430481175307" CI_START="0.15064123076316763" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.41927286699588273" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" I2="12.713370350761513" I2_Q="10.374063074801517" ID="CMP-001.01" LOG_CI_END="0.06704966110805988" LOG_CI_START="-0.8220561447208878" LOG_EFFECT_SIZE="-0.377503241806414" METHOD="MH" MODIFIED="2015-07-07 05:44:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2844614807711241" P_Q="0.290835804111791" P_Z="0.09604199635422092" Q="1.1157484477228916" RANDOM="NO" SCALE="44.954202188631534" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1879" TOTAL_2="2023" WEIGHT="100.0" Z="1.6643525509269532">
<NAME>Incidence of Rhesus D alloimmunisation during pregnancy</NAME>
<GROUP_LABEL_1>Anti-D</GROUP_LABEL_1>
<GROUP_LABEL_2>No anti-D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anti-D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no anti-D</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.423433218662297" CI_START="0.02071131516387042" DF="0" EFFECT_SIZE="0.17170082704063286" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.15333709673988286" LOG_CI_START="-1.6837923226286717" LOG_EFFECT_SIZE="-0.7652276129443943" MODIFIED="2012-11-13 22:23:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.10251424998028844" STUDIES="1" TAU2="0.0" TOTAL_1="927" TOTAL_2="955" WEIGHT="47.252777571227995" Z="1.6327848713696795">
<NAME>100 micrograms at 28 and 34 weeks</NAME>
<DICH_DATA CI_END="1.423433218662297" CI_START="0.02071131516387042" EFFECT_SIZE="0.17170082704063286" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.15333709673988286" LOG_CI_START="-1.6837923226286717" LOG_EFFECT_SIZE="-0.7652276129443943" ORDER="41" O_E="0.0" SE="1.07913891487438" STUDY_ID="STD-Huchet-1987" TOTAL_1="927" TOTAL_2="955" VAR="1.1645407975962543" WEIGHT="47.252777571227995"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2613850382770127E-31" CI_END="2.1830530878557557" CI_START="0.18824706517817558" DF="0" EFFECT_SIZE="0.6410564225690277" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="100.0" ID="CMP-001.01.02" LOG_CI_END="0.33906429708452696" LOG_CI_START="-0.7252717858409891" LOG_EFFECT_SIZE="-0.1931037443782311" MODIFIED="2015-05-10 01:26:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.4769620914068591" STUDIES="1" TAU2="0.0" TOTAL_1="952" TOTAL_2="1068" WEIGHT="52.747222428772005" Z="0.7111971309303967">
<NAME>50 micrograms at 28 and 34 weeks</NAME>
<DICH_DATA CI_END="2.1830530878557552" CI_START="0.18824706517817552" EFFECT_SIZE="0.6410564225690276" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.3390642970845269" LOG_CI_START="-0.7252717858409893" LOG_EFFECT_SIZE="-0.19310374437823116" MODIFIED="2015-05-06 00:45:12 +0100" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.6251962836590287" STUDY_ID="STD-Lee-1995" TOTAL_1="952" TOTAL_2="1068" VAR="0.39087039310106064" WEIGHT="52.747222428772005"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.289579562221119" CI_END="1.1665573912512275" CI_START="0.15276812161640857" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.42215255704447396" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" I2="22.45534674280655" I2_Q="20.28543972843507" ID="CMP-001.02" LOG_CI_END="0.06690610968836198" LOG_CI_START="-0.8159672612739024" LOG_EFFECT_SIZE="-0.37453057579277016" METHOD="MH" MODIFIED="2015-05-10 01:26:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.25612555960429784" P_Q="0.2626994016971481" P_Z="0.0963318306284383" Q="1.25447596598825" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1112" TOTAL_2="1185" WEIGHT="100.0" Z="1.6629031156819296">
<NAME>Incidence of Rhesus D alloimmunisation postpartum (at birth of Rh-positive infant)</NAME>
<GROUP_LABEL_1>Anti-D</GROUP_LABEL_1>
<GROUP_LABEL_2>No anti-D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anti-D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no anti-D</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.359408776392741" CI_START="0.019824297584660523" DF="0" EFFECT_SIZE="0.16416249304396216" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.13335006941634048" LOG_CI_START="-1.702802191677962" LOG_EFFECT_SIZE="-0.7847260611308108" MODIFIED="2012-11-13 22:23:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.09387925686741579" STUDIES="1" TAU2="0.0" TOTAL_1="599" TOTAL_2="590" WEIGHT="48.25768182193304" Z="1.6752802587621294">
<NAME>100 micrograms at 28 and 34 weeks</NAME>
<DICH_DATA CI_END="1.359408776392741" CI_START="0.019824297584660523" EFFECT_SIZE="0.16416249304396216" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.13335006941634048" LOG_CI_START="-1.702802191677962" LOG_EFFECT_SIZE="-0.7847260611308108" ORDER="43" O_E="0.0" SE="1.078564927267073" STUDY_ID="STD-Huchet-1987" TOTAL_1="599" TOTAL_2="590" VAR="1.1633023023306264" WEIGHT="48.25768182193304"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2511777290050534" CI_START="0.19512518159123463" DF="0" EFFECT_SIZE="0.6627680311890838" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.3524097836185422" LOG_CI_START="-0.7096866797576646" LOG_EFFECT_SIZE="-0.17863844806956117" MODIFIED="2012-11-13 22:24:00 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5096973128959061" STUDIES="1" TAU2="0.0" TOTAL_1="513" TOTAL_2="595" WEIGHT="51.74231817806695" Z="0.6593090864034831">
<NAME>50 micrograms at 28 and 34 weeks</NAME>
<DICH_DATA CI_END="2.2511777290050534" CI_START="0.19512518159123463" EFFECT_SIZE="0.6627680311890838" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.3524097836185422" LOG_CI_START="-0.7096866797576646" LOG_EFFECT_SIZE="-0.17863844806956117" MODIFIED="2012-08-03 01:10:36 +0100" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.6238807200494689" STUDY_ID="STD-Lee-1995" TOTAL_1="513" TOTAL_2="595" VAR="0.38922715284944387" WEIGHT="51.74231817806695"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6459717169966126" CI_END="1.622993595621732" CI_START="0.09544399454758386" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3935797147863239" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" I2="39.24561463153878" I2_Q="36.98935359354999" ID="CMP-001.03" LOG_CI_END="0.21031680609140163" LOG_CI_START="-1.0202513927485486" LOG_EFFECT_SIZE="-0.4049672933285735" METHOD="MH" MODIFIED="2015-08-10 18:16:30 +0100" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="0.19950815592616422" P_Q="0.20775053959135292" P_Z="0.19704793729020442" Q="1.5870333936101888" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.46706431650186614" TOTALS="YES" TOTAL_1="985" TOTAL_2="1063" WEIGHT="100.0" Z="1.290007836361948">
<NAME>Incidence of Rhesus D alloimmunisation postpartum (at birth of Rh-positive infant and follow-up, up to 12 months)</NAME>
<GROUP_LABEL_1>Anti-D</GROUP_LABEL_1>
<GROUP_LABEL_2>No anti-D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anti-D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no anti-D</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.146787186776644" CI_START="0.017495598230319487" DF="0" EFFECT_SIZE="0.1416464891041162" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.05948283186488419" LOG_CI_START="-1.7570712030133253" LOG_EFFECT_SIZE="-0.8487941855742206" MODIFIED="2015-05-10 01:26:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06701007673041466" STUDIES="1" TAU2="0.0" TOTAL_1="472" TOTAL_2="468" WEIGHT="32.54103416263855" Z="1.8316064395232985">
<NAME>100 micrograms at 28 and 34 weeks</NAME>
<DICH_DATA CI_END="1.1467871867766442" CI_START="0.017495598230319487" EFFECT_SIZE="0.14164648910411623" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.05948283186488428" LOG_CI_START="-1.7570712030133253" LOG_EFFECT_SIZE="-0.8487941855742206" MODIFIED="2015-05-10 01:26:22 +0100" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="1.0670528321749555" STUDY_ID="STD-Huchet-1987" TOTAL_1="472" TOTAL_2="468" VAR="1.138601746652594" WEIGHT="32.54103416263855">
<FOOTNOTE>Followed up at 2 to 12 months postpartum.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9104104944149245" CI_START="0.21733391125828963" DF="0" EFFECT_SIZE="0.6443578081004981" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.28112669515591987" LOG_CI_START="-0.6628725041290654" LOG_EFFECT_SIZE="-0.1908729044865728" MODIFIED="2015-05-10 01:26:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.42801445244536207" STUDIES="1" TAU2="0.0" TOTAL_1="513" TOTAL_2="595" WEIGHT="67.45896583736145" Z="0.792593931650778">
<NAME>50 micrograms at 28 and 34 weeks</NAME>
<DICH_DATA CI_END="1.9104104944149245" CI_START="0.21733391125828963" EFFECT_SIZE="0.6443578081004981" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.28112669515591987" LOG_CI_START="-0.6628725041290654" LOG_EFFECT_SIZE="-0.1908729044865728" MODIFIED="2015-05-10 01:26:22 +0100" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="0.5545098025313999" STUDY_ID="STD-Lee-1995" TOTAL_1="513" TOTAL_2="595" VAR="0.30748112110341214" WEIGHT="67.45896583736145">
<FOOTNOTE>Follow up at 6 months postpartum and later. Note: 1 of the 5 women in the intervention group had a recognisable potentially sensitising event, for which additional anti-D was not given; the authors considered it may therefore be inappropriate to include this patient among the failures of prophylaxis</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0449187571626433" CI_START="0.005970903830201237" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.11049892868074686" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.3106760585453965" LOG_CI_START="-2.2239599236849554" LOG_EFFECT_SIZE="-0.9566419325697795" METHOD="MH" MODIFIED="2015-07-07 05:55:56 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.13900952021531224" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="362" TOTAL_2="360" WEIGHT="100.0" Z="1.4794895575400706">
<NAME>Incidence of Rhesus D alloimmunisation postpartum (after birth of Rh-positive infant at 2 to 12 months): primigravidae</NAME>
<GROUP_LABEL_1>Anti-D</GROUP_LABEL_1>
<GROUP_LABEL_2>No anti-D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anti-D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no anti-D</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0449187571626424" CI_START="0.005970903830201237" EFFECT_SIZE="0.11049892868074686" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3106760585453963" LOG_CI_START="-2.2239599236849554" LOG_EFFECT_SIZE="-0.9566419325697795" MODIFIED="2015-05-06 04:14:30 +0100" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="1.4888577226125705" STUDY_ID="STD-Huchet-1987" TOTAL_1="362" TOTAL_2="360" VAR="2.21669731818309" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8825016311423065" CI_START="0.4091932859066892" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6009274018258224" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="67" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.05428448322575088" LOG_CI_START="-0.38807150085821057" LOG_EFFECT_SIZE="-0.22117799204198071" METHOD="MH" MODIFIED="2015-07-07 05:56:12 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.009391329687263816" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="927" TOTAL_2="957" WEIGHT="100.0" Z="2.5974700972492974">
<NAME>Incidence of positive Kleihauer test (32 to 35 weeks' gestation)</NAME>
<GROUP_LABEL_1>Anti-D</GROUP_LABEL_1>
<GROUP_LABEL_2>No anti-D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anti-D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no anti-D</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8825016311423064" CI_START="0.4091932859066892" EFFECT_SIZE="0.6009274018258224" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="67" LOG_CI_END="-0.05428448322575093" LOG_CI_START="-0.38807150085821057" LOG_EFFECT_SIZE="-0.22117799204198071" MODIFIED="2015-05-06 00:35:09 +0100" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.19606814642969156" STUDY_ID="STD-Huchet-1987" TOTAL_1="927" TOTAL_2="957" VAR="0.03844271804437497" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7901657416336786" CI_START="0.4620446856608618" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6042283357416423" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="119" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.10228180348521952" LOG_CI_START="-0.33531602055326454" LOG_EFFECT_SIZE="-0.21879891201924204" METHOD="MH" MODIFIED="2015-07-07 05:56:20 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="2.3280237294334068E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="599" TOTAL_2="590" WEIGHT="100.0" Z="3.680472274069893">
<NAME>Incidence of positive Kleihauer test (at birth of Rh-positive infant)</NAME>
<GROUP_LABEL_1>Anti-D</GROUP_LABEL_1>
<GROUP_LABEL_2>No anti-D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anti-D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no anti-D</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7901657416336786" CI_START="0.4620446856608618" EFFECT_SIZE="0.6042283357416423" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="119" LOG_CI_END="-0.10228180348521952" LOG_CI_START="-0.33531602055326454" LOG_EFFECT_SIZE="-0.21879891201924204" ORDER="39" O_E="0.0" SE="0.13688545264374816" STUDY_ID="STD-Huchet-1987" TOTAL_1="599" TOTAL_2="590" VAR="0.01873762714548382" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5430762273200767" CI_START="0.5900467586677554" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9541944908180301" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.18838738055879115" LOG_CI_START="-0.2291135710243921" LOG_EFFECT_SIZE="-0.020363095232800464" METHOD="MH" MODIFIED="2015-07-07 05:56:26 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.8483770014960255" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="599" TOTAL_2="590" WEIGHT="100.0" Z="0.19118966372988636">
<NAME>Incidence of positive Kleihauer test (Kleihauer &gt; 1/10,000, Rh-positive infant)</NAME>
<GROUP_LABEL_1>Anti-D</GROUP_LABEL_1>
<GROUP_LABEL_2>No anti-D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anti-D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no anti-D</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5430762273200767" CI_START="0.5900467586677554" EFFECT_SIZE="0.9541944908180301" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="32" LOG_CI_END="0.18838738055879115" LOG_CI_START="-0.2291135710243921" LOG_EFFECT_SIZE="-0.020363095232800464" ORDER="40" O_E="0.0" SE="0.2452421256230029" STUDY_ID="STD-Huchet-1987" TOTAL_1="599" TOTAL_2="590" VAR="0.06014370018008874" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.299991897600366" CI_START="0.028840380517727176" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2575512405609493" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="100.0" ID="CMP-001.08" LOG_CI_END="0.3617263060899193" LOG_CI_START="-1.5399990138673456" LOG_EFFECT_SIZE="-0.5891363538887131" METHOD="MH" MODIFIED="2015-07-07 05:56:32 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.22461172818721975" Q="3.951024013903149E-32" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="927" TOTAL_2="955" WEIGHT="100.0" Z="1.2143562726830284">
<NAME>Neonatal morbidity (jaundice)</NAME>
<GROUP_LABEL_1>Anti-D</GROUP_LABEL_1>
<GROUP_LABEL_2>No anti-D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anti-D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no anti-D</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.299991897600365" CI_START="0.0288403805177272" EFFECT_SIZE="0.2575512405609493" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3617263060899191" LOG_CI_START="-1.5399990138673454" LOG_EFFECT_SIZE="-0.5891363538887131" ORDER="1" O_E="0.0" SE="1.117082866635053" STUDY_ID="STD-Huchet-1987" TOTAL_1="927" TOTAL_2="955" VAR="1.2478741309295875" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-08-10 18:09:35 +0100" MODIFIED_BY="Heather Maxwell">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-08-10 18:09:35 +0100" MODIFIED_BY="Heather Maxwell" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-08-10 18:09:35 +0100" MODIFIED_BY="Heather Maxwell" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATEAAAGRCAIAAACCGxPRAAARdElEQVR42u3dP29dRRPH8SshIQoX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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS>


<EXTENSION ID="AFF_15869_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="15869"><ADDRESS><DEPARTMENT>ARCH: Australian Research Centre for Health of Women and Babies, Robinson Research Institute, Discipline of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>The University of Adelaide</ORGANISATION><ADDRESS_1>Women's and Children's Hospital</ADDRESS_1><ADDRESS_2>72 King William Road</ADDRESS_2><CITY>Adelaide</CITY><ZIP>5006</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 8 81617647</PHONE_1><PHONE_2>+61 8 81617000</PHONE_2><FAX_1>+61 8 81617652</FAX_1></ADDRESS></ALIAS></EXTENSION><EXTENSION ID="AFF_4841_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="4841"><ADDRESS><DEPARTMENT>ARCH: Australian Research Centre for Health of Women and Babies, Robinson Research Institute, Discipline of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>The University of Adelaide</ORGANISATION><CITY>Adelaide</CITY><REGION>SA</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 8 8161 7073</PHONE_1></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>